ReVivo Medical has announced that it has raised $2 million which will allow it to complete the 500 surgical procedures of its clinical trial.
Gary Mittleman, ReVivo Medical president and CEO, said: “Raising funds is never an easy task and we are grateful to the support of the 57 angel investors who have helped to fund our development activities over the last six years.”
“Attaining FDA clearance is the final step before offering a commercial product and this trial is our gateway to achieving this goal,” added Eric Ledet, the company’s chief science officer. “We expect to begin enrolling patients for our study shortly.”
Study participants will receive ReVivo Medical’s next-generation design anterior cervical plate and interbody cages used in anterior cervical discectomy and fusion procedures. The study will take place at the Albany Medical Centre and the Cleveland Clinic in the USA.
“Our cervical plate and cage implants are designed to improve bone formation and achieve a superior rate and quality of fusion as compared to the commonly used devices of today,” explains Ledet. “Additionally, the designs of our implants incorporate unique features that are intended to make them easier for the surgeon to use.”
